- Home
- CNOB vs OCS Comparison
CNOB vs OCS Comparison
Compare CNOB & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNOB
- OCS
- Stock Information
- Founded
- CNOB 1982
- OCS 2003
- Country
- CNOB United States
- OCS Switzerland
- Employees
- CNOB N/A
- OCS N/A
- Industry
- CNOB Major Banks
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- CNOB Finance
- OCS Health Care
- Exchange
- CNOB Nasdaq
- OCS Nasdaq
- Market Cap
- CNOB 1.2B
- OCS 956.4M
- IPO Year
- CNOB 1996
- OCS N/A
- Fundamental
- Price
- CNOB $23.29
- OCS $17.73
- Analyst Decision
- CNOB Buy
- OCS Strong Buy
- Analyst Count
- CNOB 1
- OCS 3
- Target Price
- CNOB $31.00
- OCS $35.33
- AVG Volume (30 Days)
- CNOB 310.7K
- OCS 13.7K
- Earning Date
- CNOB 07-29-2025
- OCS 08-26-2025
- Dividend Yield
- CNOB 3.07%
- OCS N/A
- EPS Growth
- CNOB N/A
- OCS N/A
- EPS
- CNOB 0.82
- OCS N/A
- Revenue
- CNOB $241,854,000.00
- OCS $847,333.00
- Revenue This Year
- CNOB $46.52
- OCS $10.23
- Revenue Next Year
- CNOB $29.92
- OCS $912.87
- P/E Ratio
- CNOB $28.80
- OCS N/A
- Revenue Growth
- CNOB N/A
- OCS N/A
- 52 Week Low
- CNOB $20.08
- OCS $10.79
- 52 Week High
- CNOB $29.31
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- CNOB 40.17
- OCS 41.73
- Support Level
- CNOB $23.73
- OCS $17.53
- Resistance Level
- CNOB $24.72
- OCS $18.57
- Average True Range (ATR)
- CNOB 0.65
- OCS 0.56
- MACD
- CNOB -0.24
- OCS 0.01
- Stochastic Oscillator
- CNOB 8.33
- OCS 30.39
About CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.